Cyteir Therapeutics Stock (NASDAQ:CYT)
Previous Close
$3.09
52W Range
$1.65 - $3.19
50D Avg
$3.09
200D Avg
$2.86
Market Cap
$108.71M
Avg Vol (3M)
$167.62K
Beta
0.10
Div Yield
-
CYT Company Profile
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
CYT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| NUVB | Nuvation Bio Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| FHTX | Foghorn Therapeutics Inc. |
| GBIO | Generation Bio Co. |
| CSBR | Champions Oncology, Inc. |
| GRPH | LENZ Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| RZLT | Rezolute, Inc. |
| NKTX | Nkarta, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| NLTX | Neurogene Inc. |
| ELYM | Eliem Therapeutics, Inc. |